Inhye E. Ahn

Oncology
450 Brookline Ave
Boston, MA 02215

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 58 publications

SAVE, Safe Accelerated Venetoclax Escalation: A phase Ib study of obinutuzumab plus venetoclax with daily ramp-up in CLL.

SAVE, Safe Accelerated Venetoclax Escalation: A phase Ib study of obinutuzumab plus venetoclax with daily ramp-up in CLL.

Journal: Blood advances
Published: March 11, 2026

Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL.

Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL.

Journal: Blood advances
Published: July 14, 2025

Sudden death and asymptomatic arrhythmia in chronic lymphocytic leukemia patients treated with ibrutinib.

Sudden death and asymptomatic arrhythmia in chronic lymphocytic leukemia patients treated with ibrutinib.

Journal: Heart rhythm
Published: July 02, 2025

Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockade.

Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockade.

Journal: Blood neoplasia
Published: June 24, 2025

A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study.

A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study.

Journal: Blood
Published: June 06, 2025

A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study.

A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study.

Journal: Blood
Published: June 06, 2025

Activation and exhaustion of CD8 T cells in patients with chronic lymphocytic leukemia treated with ibrutinib and pembrolizumab.

Activation and exhaustion of CD8 T cells in patients with chronic lymphocytic leukemia treated with ibrutinib and pembrolizumab.

Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: March 20, 2025

Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.

Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 18, 2025

State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee.

State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee.

Journal: Blood cancer journal
Published: March 09, 2025

Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia.

Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia.

Journal: Blood advances
Published: January 24, 2025

Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.

Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 07, 2024

Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL.

Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL.

Journal: Blood advances
Published: August 12, 2024
Showing 1-12 of 58

Last Updated: 09/26/2026